晚期非小细胞肺癌脑转移的靶向治疗

Targeted therapy in non-small cell lung cancer patients with brain metastasis

脑转移是非小细胞肺癌（NSCLC）常见的转移部位，出现脑转移的患者生活质量下降，预后不佳。目前脑转移的主要治疗方式为全脑放疗，常规化疗对脑转移治疗效果不佳。近期多个个案报道和小规模的回顾性研究发现以吉非替尼和厄洛替尼为代表的表皮生长因子受体-酪氨酸激酶抑制剂对NSCLC脑转移体现出良好治疗效果。特别是对于存在表皮生长因子受体基因突变的患者，效果更加显著。提示该类药物可能是治疗NSCLC脑转移的一个好选择。

Brain is one of the most frequent sites of metastasis in patients with non-small cell lung cancer （NSCLC）. Patients with central nervous system （CNS） metastasis generally suffer from deterioration of performance status and therefore do not have a long survival time. Recently, several studies have documented the effectiveness of targeted therapy in the treatment of CNS metastasis of NSCLC. These treatments might be effective for CNS metastasis of NSCLC especially in epidermal growth factor receptor gene mutation-type cases.